European Directorate for the Quality of Medicines

European Directorate for the Quality of Medicines & HealthCare
	EDQM Building, Strasbourg
Abbreviation	EDQM
Predecessor	European Pharmacopoeia (1964-1996); European Department for the Quality of Medicines (1996-2007);
Formation	1964
Type	Administrative entity of the Council of Europe
Purpose	Protection of public health
Headquarters	Strasbourg, France
Director	Dr Susanne Keitel
Staff	Over 340 (as of February 2020)
Website	www.edqm.eu

Last updated July 31, 2020

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia (an international treaty adopted by the Council of Europe in 1964: CETS 50,^[1] Protocol^[2]). The signatories to the convention – 39 member states and the European Union (EU) as of October 2018 – are committed to achieving harmonisation of the quality standards for safe medicines throughout the European continent and beyond (in addition to the member states there are 28 Observers, including WHO). The EDQM’s standards are published in the European Pharmacopoeia (officially abbreviated to Ph. Eur.), which is recognised as a scientific benchmark worldwide and is legally binding in member states.

The EDQM’s mission
Activities related to the quality of medicines
The European Pharmacopoeia: Setting quality specifications and pharmaceutical reference standards
The Certification procedure: Evaluating quality in the manufacture of substances for pharmaceutical use and the related inspections programme
The OMCL Network: quality control of medicines on the market
Pharmaceutical care and combating counterfeit medicines
Activities related to patient and consumer protection
Blood Transfusion
Organ, tissue and cell transplantation
Cosmetics and food contact materials
References
External links

Today, direct reference is made in the EU’s pharmaceutical legislation to the European Pharmacopoeia and to other activities under the responsibility of the EDQM (e.g. the Certification procedure and the OMCL Network – see below), demonstrating the strong collaboration between the European organisations in protecting public health.

The EDQM is also involved in a number of international platforms for collaboration and harmonisation, such as the Pharmacopoeial Discussion Group (PDG), the International Generic Drug Regulators Programme (IGDRP), the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (jointly referred to as PIC/S) and the International API Inspection Programme (co-ordinated by the European Medicines Agency, or EMA).

In addition to the PDG, the EDQM is actively involved in a number of other international harmonisation initiatives, such as the World Health Organization (WHO) initiative to draft “Good Pharmacopoeial Practices” (GPhP), which may serve as a basis for future work-sharing and collaboration amongst pharmacopoeias worldwide. The EDQM also collaborates with WHO in a number of other ways; for example, the EDQM establishes, monitors and distributes WHO International Standards for Antibiotics (ISA) and WHO International Chemical Reference Substances (ICRS).

In this context, the EDQM plays an essential role in the complex regulatory framework for medicines in Europe. Its fundamental aim is to protect public health by enabling the development, supporting the implementation, and monitoring the application of quality standards for safe medicines and their safe use.

The EDQM’s mission

Within the Council of Europe, the EDQM’s mission is to contribute to the basic human right of access to good quality medicines and healthcare, and to promote and protect human and animal health by:

establishing and providing official standards which apply to the manufacture and quality control of medicines in all the signatory states of the Convention for the Elaboration of a European Pharmacopoeia and beyond;
granting Certificates of suitability which verify the compliance of pharmaceutical substances with European Pharmacopoeia standards and carrying out inspections of manufacturers of these substances;
co-ordinating a network of Official Medicines Control Laboratories (OMCLs) to collaborate and share expertise between member states and optimise the use of available resources, with the aim of achieving effective public quality control of medicines in Europe and beyond;
proposing ethical, safety and quality standards for blood transfusions (collection, preparation, storage, distribution and appropriate use of blood components) and the transplantation of organs, tissues and cells;
working with national, European and international organisations in efforts to combat counterfeiting/falsification of medical products and similar crimes;
providing policies and model approaches for the safe use of medicines in Europe, including guidelines on pharmaceutical care; and
establishing standards for cosmetics and food contact materials and co-ordinating the public control of cosmetics.

Activities related to the quality of medicines

The European Pharmacopoeia: Setting quality specifications and pharmaceutical reference standards

Published and regularly updated by the EDQM/Council of Europe in English and French, the two official languages of the Council of Europe, the European Pharmacopoeia is a single reference work for official European quality standards. It thus helps define the requirements for obtaining a marketing authorisation of a medicinal product in Europe, but its standards are recognised as a scientific benchmark worldwide in the field of quality control for human and veterinary medicines. The European Pharmacopoeia’s common, harmonised quality standards define strict specifications for medicines and substances used in their manufacture, which apply throughout the product’s entire life-cycle. When adopted, they are legally binding and become mandatory on the same date in the 39 Council of Europe member states that are signatory states to the European Pharmacopoeia Convention, applying to all medicines on their markets.^[1]

The contents of the European Pharmacopoeia are elaborated and updated by the European Pharmacopoeia Commission, which is responsible for overseeing the practical work of 800 or so experts in every field of the pharmaceutical sciences – all volunteers – who participate in more than 70 Groups of Experts and Working Parties. The European Pharmacopoeia Commission decides on the work programme, appoints the experts, and adopts the monographs (Articles 6 and 7, European Pharmacopoeia Convention).^[1] It meets three times a year in Strasbourg (France) and all technical decisions are taken by a unanimous vote. The EDQM of the Council of Europe provides the scientific secretariat and logistical support for the work of the European Pharmacopoeia Commission, and facilitates the activities of its Groups of Experts and Working Parties.

The texts of the European Pharmacopoeia cover all therapeutic areas and consist of:

individual monographs describing legally binding quality standards for substances used in the manufacture of medicines or medicine ingredients (including chemicals, herbals, etc.);
individual monographs describing legally binding quality standards for finished products;
general monographs describing legally binding quality standards for classes of substances (such as fermentation products) or for the dosage forms that medicines can take (tablets, capsules, injections, etc.); and
general methods of analysis of substances used in the manufacture of medicines, which are not legally binding and may also be used for substances and medicines not described in the European Pharmacopoeia. All analytical methods described in the monographs are experimentally verified. In addition, the EDQM is also responsible for establishing official reference standards, which are an essential component of most texts of the European Pharmacopoeia (e.g. in order to carry out the tests described), and supplying these to users of the European Pharmacopoeia. Users include manufacturers located both in Europe and around the world, as well as national and European authorities involved in controlling the quality of medicines. The EDQM publishes a new edition of the European Pharmacopoeia every three years.

The Certification procedure: Evaluating quality in the manufacture of substances for pharmaceutical use and the related inspections programme

The EDQM implements a quality evaluation programme for active pharmaceutical ingredients (APIs) and excipients used in the manufacture of medicines. The Certification of Suitability to the monographs of the European Pharmacopoeia procedure was established in 1992 as a pilot phase and turned into a routine procedure in 1994 for chemical substances, and was expanded in 2003 to include herbal drugs and herbal drug preparations.^[3] It aims to evaluate whether the relevant European Pharmacopoeia monograph(s) can be used to adequately control the quality and impurity profile of an API or excipient produced and/or distributed by a particular manufacturer. The procedure is complemented by an inspection programme of manufacturing and/or distribution sites.

The Certification procedure is not compulsory – it is a service that is offered to manufacturers, who can use a Certificate of Suitability (CEP) in an application for a new market authorisation (MAA) or for a variation of an existing MAA. The Certification procedure centralises the evaluation of data for the benefit of regulatory authorities and industry alike, thus saving time and resources. For example, on average it takes three days for a regulatory authority to assess an Active Substance Master File (ASMF), which is the document submitted by a manufacturer of a medicine as part of its application for MAA (the ASMF contains complete information on an API or finished drug dosage form).

Also, the Certification procedure provides the European Pharmacopoeia Commission with current information on the quality of substances on the European market, thus helping to identify whether or not a revision of specific European Pharmacopoeia monographs is needed.

CEPs – which are referred to in EU pharmaceutical legislation – are recognised by the European Pharmacopoeia member states and by a number of other countries and regions, such as Australia, Canada, New Zealand, Saudi Arabia, Singapore, South Africa, Taiwan and Tunisia. An increasing number of licensing authorities worldwide accept CEPs to support (fully or partially) the data related to the quality of APIs used in medicinal products.

In order for a specific manufacturer to be granted a CEP, the EDQM’s panel of assessors (drawn from national medicines agencies throughout Europe) review a detailed dossier submitted by the manufacturer. This dossier describes the manufacturing process and the tests performed on the raw materials and on the substance produced, as well as the necessary in-process controls. The manufacturer must demonstrate that its product complies with the quality standards required by the European Pharmacopoeia and EU legislation and, in particular, that the monograph can be used to control impurities. The applicant must also agree to comply with the relevant Good Manufacturing Practice (GMP) as defined in Part II of the EU GMP Guide, and to accept a site inspection at any time at the request of the EDQM.

The OMCL Network: quality control of medicines on the market

On 26 May 1994, in a new co-operative venture in the area of the quality control of medicines for human and veterinary use on the market, the European Commission and the Council of Europe decided to establish a European Network of Official Medicines Control Laboratories (OMCLs) on a co-funded basis. The OMCL Network, which is open to member states and observers of the European Pharmacopoeia Convention, thus ensures that patients receive the same quality of pharmaceutical products throughout Europe.

This international collaboration reduces public health expenses by sharing resources, and also influences future development through harmonised common standards. The sharing of workloads, resources and expertise among the OMCLs makes it possible to avoid duplication of work and gives them access to the latest technologies and selective methods of different types of analysis. The EDQM is responsible for co-ordinating the Network’s technical activities and ensuring the smooth running of its various joint programmes.

This network is made up of independent public laboratories that have been appointed by their respective national authority.

The network performs studies on medicinal products already on the market (market surveillance studies, MSSs). The EDQM organises inter-laboratory testing activities for OMCLs to improve their laboratory performance (Proficiency Testing Scheme studies) and promotes common quality management systems in all OMCLs to enable their work-sharing and mutual recognition of test results.

The EDQM is also the technical secretariat for the Official Control Authority Batch Release (OCABR) procedures of the Network for certain products (e.g. vaccines, blood- and plasma-derived products, immunological veterinary medicinal products) and in testing activities related to counterfeit medicines. The OCABR procedure guarantees that for the vast majority of, for example, vaccines used in the European Union, no batch of vaccine is released for marketing in member states without first undergoing an independent quality examination by a laboratory of the OMCL Network.

Pharmaceutical care and combating counterfeit medicines

Worldwide, it is estimated that half of all medicines are inappropriately prescribed, dispensed or sold, and that half of all patients fail to take their medicines properly. Errors relating to medication use, lack of documentation on how medicines are prescribed, used and dispensed, as well as insufficient communication have a considerable impact on national mortality rates and levels of ill-health. Therefore the safe and appropriate use of medicines, which depends on the right information being available to everyone that needs it, is as important as product quality.

In order to face this challenge, the European Committee on Pharmaceuticals and Pharmaceutical Care,^[4] co-ordinated by the EDQM, oversees the work of experts in three main areas, which today also has to take into account constraints on public health budgets and social inequality in access to healthcare:

The classification of medicines authorised in Europe into prescription and non-prescription medicines: Although individual countries are responsible for classifying medicines in this way, the EDQM’s committee of experts for this activity makes classification recommendations, which, due to the range of European Pharmacopoeia member states that participate in this activity, can include medicines that are not licensed for use in the EU. These recommendations are updated annually and published on the EDQM’s website. The EDQM also hosts the Melclass database, which presents the classification status of medicines in European Pharmacopoeia member states.
Setting quality and safety standards in pharmaceutical practices and pharmaceutical care: Public authorities and the sectors of the pharmaceutical industry that focus on manufacturing and distribution devote a lot of their resources to the quality, safety and efficacy of medicines. However, the safe and appropriate use of medicines is just as important as product quality for ensuring that a patient obtains the best possible outcome from his/her medicine. The EDQM’s committee of experts for this activity develops scientific indicators for measuring the quality of pharmaceutical care in Europe. Pharmaceutical care is understood as a quality concept and working method for the responsible provision of medicine therapy for definite outcomes in the interest of patients’ quality of life. The indicators developed by the EDQM provide information that is of practical use on a day-to-day basis for policy-makers and professional associations, helping to make healthcare systems more responsible and cost-effective.
Preventing and managing risks posed by counterfeit/falsified medicines: Counterfeit/falsified medicines pose a growing and real threat to public health in Europe. These medicines may contain low quality ingredients or the wrong doses, they may be deliberately mislabelled or have fake packaging or ingredients. To combat this problem, the Council of Europe established the MEDICRIME Convention (CETS 211).^[5] It is the first international treaty that criminalises the counterfeiting of medical products and similar crimes with a view to public health protection. The convention entered into force on 1 January 2016.

Activities related to patient and consumer protection

Blood Transfusion

The work of the EDQM in the area of blood transfusion is co-ordinated by the European Committee on Blood Transfusion. This committee consists of 65 representatives drawn from 35 Council of Europe member states and signatories of the European Pharmacopoeia Convention, as well as 10 observer states and other observers such as the EU Commission and WHO. These experts work together on the ethical, legal and organisational aspects of blood transfusion. The “Guide to the preparation, use and quality assurance of blood components”^[6]^[7] contains recommendations on blood collection, blood components, technical procedures, transfusion practices and quality systems for blood establishments.

More specifically, through its regular work the Committee assists Council of Europe member states to improve their blood transfusion services, ensures the transfer of knowledge and expertise through training and networking, and monitors practices in Europe and assesses epidemiological risks, in particular those related to the emergence of new infectious agents transmissible by blood transfusion.

Organ, tissue and cell transplantation

The work of the Council of Europe in the area of organ, tissue and cell transplantation began in 1987. The guiding principles for the EDQM’s activities in this area are to guarantee human rights and dignity and to protect donors and recipients. This latter principle means improving and promoting strict standards for quality and safety in order to protect not only the donor and recipient, but also the graft itself, which is a rare and precious resource.

The European Committee on Organ Transplantation is the steering committee in charge of transplantation activities. This committee consists of 91 experts representing 54 countries, plus the EU Commission and WHO. It actively promotes the non-commercialisation of donations, the fight against organ/tissue trafficking and the development of ethical, quality and safety standards in the field of organ, tissue and cell transplantation. An important part of their work is the elaboration of guides such as the “Guide to quality and safety of organs for transplantation”^[8]^[9] and the “Guide to the quality and safety of tissues and cells for human application”.

The EDQM organises a European Day for Organ Donation and Transplantation together with a different member state every year, to promote organ donation and transplantation in its member states.

Cosmetics and food contact materials

Since 1 January 2009, the EDQM has also been engaged in efforts to strengthen consumer health protection in Europe, with a focus on the safe use and quality of cosmetics and materials designed for packaging or other purposes involving contact with foodstuffs.

The Consumer Health Protection Committee is in charge of managing the work programme. It has two groups of experts – the Committee of Experts on Cosmetic Products and the Committee of Experts on Food Contact Materials – that examine health-related matters and prepare reports and recommendations concerning regulatory approaches.

A network of Official Cosmetics Control Laboratories (OCCLs) was established in 2010 to share the work linked to cosmetics surveillance by strengthening inter-laboratory collaboration and the sharing of resources among market surveillance authorities. Several control laboratories in Asia also take part in the work programme.

Network activities include market-surveillance studies, analytical development, proficiency testing scheme studies and the implementation of harmonised QM systems. Priority is given to testing products that may present a health risk for consumers, either linked to the presence of prohibited or restricted substances (according to EU legislation) or to trace metals. In addition, the Network also publishes test methods after performing inter-laboratory trials to confirm that these methods are fit for purpose.

Related Research Articles

Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.

A pharmacopoeia, pharmacopeia, or pharmacopoea, in its modern technical sense, is a book containing directions for the identification of compound medicines, and published by the authority of a government or a medical or pharmaceutical society.

Good manufacturing practices (GMP) are the practices required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS).

A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP).
The BAN is also the official name used in some countries across the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming consistency worldwide. There is also a British Approved Name (Modified) (BANM).

Regulation of therapeutic goods regulation designed mainly to protect the health and safety of the population, aiming at ensuring the safety, quality, and efficacy of the therapeutic goods

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an initiative that brings together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceutical product development and registration.

The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom. It is an annually published collection of quality standards for UK medicinal substances. It is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing.

In the experimental (non-clinical) research arena, good laboratory practice or GLP is a quality system of management controls for research laboratories and organizations to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of products in development for human or animal health through non-clinical safety tests; from physio-chemical properties through acute to chronic toxicity tests.

NHS Blood and Transplant is an executive non-departmental public body of the United Kingdom's Department of Health and Social Care. It was established on 1 October 2005 to take over the responsibilities of two separate NHS agencies: UK Transplant, founded by Dr. Geoffrey Tovey in 1972, and the National Blood Service. Its remit is to provide a reliable, efficient supply of blood, organs and associated services to the NHS. Since NHSBT was established, the organisation has maintained or improved the quality of the services delivered to patients, stabilised the rising cost of blood, and centralised a number of corporate services.

The European Pharmacopoeia is a major regional pharmacopoeia which provides common quality standards throughout the pharmaceutical industry in Europe to control the quality of medicines, and the substances used to manufacture them. It is a published collection of monographs which describe both the individual and general quality standards for ingredients, dosage forms, and methods of analysis for medicines. These standards apply to medicines for both human and veterinary use.

The International Pharmacopoeia is a pharmacopoeia issued by the World Health Organization as a recommendation, with the aim to provide international quality specifications for pharmaceutical substances and dosage forms, together with supporting general methods of analysis, for global use. Its texts can be used or adapted by any WHO member state wishing to establish legal pharmaceutical requirements.

ISBT 128 is a global standard for the identification, labeling, and information transfer of medical products of human origin across international borders and disparate health care systems.

The Health Sciences Authority is a statutory board under the Ministry of Health of the Singapore Government, next to Outram Park MRT station.

The following outline is provided as an overview of and topical guide to clinical research:

The National Institute for Biological Standards and Control (NIBSC) is a government agency that works in the field of biological standardisation. It is part of the UK Medicines and Healthcare products Regulatory Agency (MHRA). It is responsible for developing and producing over 90% of the biological international standards in use around the world.

The Committee on Herbal Medicinal Products (HMPC), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on herbal medicines.

An Official Medicines Control Laboratory (OMCL) is an official laboratory for the investigation and independent quality control of medicinal products and other similarly regulated substances.

The Spanish Agency of Medicines and Medical Devices (AEMPS) is a regulatory agency of the Government of Spain that acts as the highest sanitary authority in terms of medical safety on medicines, health products, cosmetics and personal care products.

References

External links

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[:0-1] 1 2 3 "Convention on the Elaboration of a European Pharmacopoeia CETS No.: 050, Treaty Office, Council of Europe"

[2] "Protocol to the Convention on the Elaboration of a European Pharmacopoeia"

[3] "Resolution AP-CSP (07) 1 (adopted by the Public Health Committee (Partial Agreement) (CD-P-SP) on 21/02/2007) Certification of suitability to the monographs of the European Pharmacopoeia (revised version)" (PDF).

[4] "(CD-P-PH/PC) Committee of Experts on quality and safety standards in pharmaceutical practices and pharmaceutical care".

[5] "Council of Europe Convention on the Counterfeiting of Medical Products and similar Crimes involving Threats to Public Health".

[6] "Resolution CM/Res(2008)5 on donor responsibility and on limitation to donation of blood and blood components" (PDF).

[7] "Terms of Reference of the European Committee on Blood Transfusion (CD-P-TS), valid from 1 Jan 2016 until 31 Dec 2017" (PDF).

[8] "Terms of reference of the European Committee (Partial Agreement) on organ transplantation (CD-P-TO)".

[9] "Resolutions which are the basis for the quality and safety of organs for transplantation Guide".